Davis J L, Taskintuna I, Freeman W R, Weinberg D V, Feuer W J, Leonard R E
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Fla, USA.
Arch Ophthalmol. 1997 Jun;115(6):733-7. doi: 10.1001/archopht.1997.01100150735008.
To describe intraocular inflammation due to treatment with intravenous cidofovir dihydrate for cytomegalovirus retinitis.
Retrospective cohort.
Three university outpatient ophthalmology clinics.
All patients treated with intravenous cidofovir therapy before October 31, 1996.
Treatment with intravenous cidofovir was given according to standardized protocols. Intraocular inflammation was treated according to the best medical judgment.
The presence of new intraocular inflammation, the severity of inflammation, visual acuity, and intraocular pressure.
Eleven cases of iritis (26%) occurred among 43 patients. In 6 cases, the iritis was bilateral. Patients who experienced iritis were more likely to have been previously treated for cytomegalovirus retinitis (P = .03), to be diabetic (P = .05), or to be receiving protease inhibitors (P < .001). Four patients and 15 control subjects had also taken rifabutin (P = .70). The onset of iritis occurred at a mean (+/-SD) of 4.9 +/- 1.8 days after a cidofovir dose and after a mean (+/-SD) of 4.2 +/- 1.6 doses of cidofovir. Six eyes of 4 patients had hypotony. Five eyes of 5 patients had a persistent decrease in visual acuity of at least 2 Snellen lines.
Acute intraocular inflammation may occur with or without hypotony after intravenous cidofovir therapy, similar to the reactions seen after intravitreous administration. Although the manifestations may be severe, they are manageable with topical corticosteroid therapy in most cases. Cidofovir therapy can be continued in some patients if medical necessity warrants, but recurrent inflammation or permanent hypotony may occur.
描述因静脉注射二水西多福韦治疗巨细胞病毒性视网膜炎而导致的眼内炎症。
回顾性队列研究。
三家大学门诊眼科诊所。
1996年10月31日前接受静脉注射西多福韦治疗的所有患者。
根据标准化方案给予静脉注射西多福韦治疗。根据最佳医学判断治疗眼内炎症。
新出现的眼内炎症的存在情况、炎症的严重程度、视力和眼压。
43例患者中有11例(26%)发生了虹膜炎,其中6例为双侧虹膜炎。发生虹膜炎的患者更有可能既往接受过巨细胞病毒性视网膜炎治疗(P = 0.03)、患有糖尿病(P = 0.05)或正在接受蛋白酶抑制剂治疗(P < 0.001)。4例患者和15名对照受试者也服用了利福布汀(P = 0.70)。虹膜炎的发作平均发生在西多福韦给药后4.9±1.8天,以及平均(±标准差)4.2±1.6剂西多福韦之后。4例患者的6只眼出现了低眼压。5例患者的5只眼视力持续下降至少2行。
静脉注射西多福韦治疗后,无论有无低眼压,均可发生急性眼内炎症,类似于玻璃体内给药后出现的反应。虽然表现可能很严重,但在大多数情况下,局部使用皮质类固醇治疗是可以控制的。如果有医学必要性,一些患者可以继续使用西多福韦治疗,但可能会发生炎症复发或永久性低眼压。